Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
In this episode of the Oncology Unplugged series, Chandler Park, MD, a genitourinary medical oncologist at Norton Cancer Institute in Louisville, Kentucky, hosted a conversation with Vivek Subbiah, MD, a medical oncologist and chief of Early-Phase Drug Development at Sarah Cannon Research Institute in Nashville, Tennessee. Dr Subbiah, an internationally recognized expert, discussed advancements in precision oncology, emphasizing the effects of next-generation sequencing and tissue-agnostic therapies on personalized cancer treatment. Dr Subbiah highlighted the transformation in genome sequencing that has taken place since the Human Genome Project, noting the reduction in sequencing costs from $3.3 billion to potentially $1 per genome. He explained how this evolution supports the expansion of precision oncology by making genomic testing accessible across diverse health care settings.